Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.
Victoria AtkinsonAdnan KhattakAndrew HaydonMelissa EastgateAmitesh RoyPrashanth PrithvirajChristian MuellerChrystelle BrignoneFrederic TriebelPublished in: Journal for immunotherapy of cancer (2021)
Efti was well tolerated in combination with pembrolizumab with encouraging antitumor activity. This warrants further clinical studies of this new combination therapy combining an antigen-presenting cell activator with an immune checkpoint inhibitor.
Keyphrases
- combination therapy
- advanced non small cell lung cancer
- single cell
- cell therapy
- genome wide
- nuclear factor
- copy number
- peripheral blood
- binding protein
- gene expression
- stem cells
- amino acid
- case report
- genome wide identification
- toll like receptor
- inflammatory response
- epidermal growth factor receptor
- mesenchymal stem cells
- dna methylation
- transcription factor